Orthopediatrics Corp (KIDS)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $844.67M
Last updated: Nov 17, 2026 at 11:05 AM ET
Orthopediatrics Corp (KIDS) Stock Forecast
Analysts expect Orthopediatrics (KIDS) to earn -$1.09 per share in the fiscal year ending Dec 31, 2026, on revenue of $271.60M. Of 9 analysts, 8 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 2 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 9 ratings average 1.78, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 89% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 3 | 33.3% |
| Buy | 5 | 55.6% |
| Hold | 1 | 11.1% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 9
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 12.1%.
- Fiscal year ending Dec 31, 2026
- -$1.09
- EPS consensus, revenue $271.60M
- Fiscal year ending Dec 31, 2027
- -$0.75
- EPS consensus, revenue $304.47M
- Next report
- Feb 24, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.09 | -$1.12 to -$1.06 | 4 | $271.60M | $271.01M to $272.00M | 8 |
| Dec 31, 2027 | -$0.75 | -$1.04 to -$0.23 | 5 | $304.47M | $303.20M to $306.80M | 8 |
Quarterly Estimates
The EPS consensus falls from -$0.22 for the quarter ending Dec 31, 2026 to -$0.30 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.22 | -$0.25 to -$0.18 | 10 | $70.39M | $67.13M to $72.97M | 10 |
| Mar 31, 2027 | -$0.30 | -$0.41 to -$0.12 | 5 | $66.93M | $65.99M to $69.30M | 7 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 4 upward and 8 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 2 | 2 |
| Fiscal year ending Dec 31, 2027 | 1 | 4 |
| Quarter ending Mar 31, 2027 | 1 | 2 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$1.05.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$1.09 | -$1.09 | -$1.09 | -$1.09 | -$1.05 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.75 | -$0.71 | -$0.71 | -$0.71 | -$0.68 | N/A |
| Quarter ending Mar 31, 2027 | -$0.30 | -$0.28 | -$0.28 | -$0.28 | -$0.28 | N/A |
Frequently Asked Questions About KIDS
What is the KIDS stock forecast?
Consensus analyst estimates put Orthopediatrics's EPS at -$1.09 for the fiscal year ending Dec 31, 2026, on revenue of $271.60M. The consensus rating from 9 analysts is Buy.
How do analysts rate KIDS stock?
Of 9 analysts covering Orthopediatrics, 3 rate it Strong Buy, 5 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from KIDS next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.09, with estimates from -$1.12 to -$1.06 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.75, with estimates from -$1.04 to -$0.23 from 5 analysts.
What revenue do analysts expect from Orthopediatrics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $271.60M, with estimates from $271.01M to $272.00M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $304.47M, with estimates from $303.20M to $306.80M.
How many analysts cover KIDS?
9 analysts rate Orthopediatrics stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
KIDS pages: Overview, Earnings, Forecast, Financials, Valuation